Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors

Core Viewpoint - Alvotech has successfully completed a private placement aimed at expanding its shareholder base and increasing the free float of Swedish Depositary Receipts (SDRs) on Nasdaq Stockholm, with significant participation from institutional investors [1][2]. Group 1: Private Placement Details - The private placement occurred on June 4, 2025, with participation from approximately 40 institutional investors [1]. - About 60% of the demand for the placement came from institutional investors based in Sweden, Norway, or the UK, while around 30% originated from US-based funds [1]. - Over 80% of the shares and SDRs allocated in the placement were sold to new investors who were not previously shareholders in Alvotech [1]. Group 2: Shareholder Base and Market Impact - The chairman and CEO of Alvotech, Róbert Wessman, expressed enthusiasm about welcoming a diverse group of new shareholders with extensive experience in healthcare and biotech investments [2]. - The placement is expected to diversify and strengthen Alvotech's shareholder base, as well as increase the free float of SDRs, with approximately 8.5 million SDRs already trading on the Swedish market [2]. Group 3: Share Transfer - All SDRs and shares allocated from the private placement have been delivered to the counterparties, involving a transfer of 7.5 million treasury shares previously held by Alvotech's subsidiary, Alvotech Manco ehf [3].